Crohns Disease News
|
|
   
|
|
Crohns Disease News Archive22-Dec-2006Holidays bring back fond memories (The Troy Messenger) Thanksgivings just seem to run together and all the memories blend into family and food. At least that's what many people say. ?My most memorable Thanksgiving was about 10 years ago when all of my children and grandchildren and great-grandchildren were there,? said Elsie Lindsey. Research and Markets : The Battle between Cimzia and Humira Will Depend On Efficacy, Convenience and Cost for ... (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of Commercial and Pipeline Insight: Inflammatory Bowel Disease - Competition Increases for the Biologics to their offering. Research & Markets: One of UCB's biggest-selling Products, Keppra, Achieved Sales Growth of 34% (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of the Espicom Business Intelligence Ltd report: UCB Prospects to 2010 to their offering. Elan, Biogen Idec submit Tysabri for Crohn's (Pharmaceutical Business Review) Elan and Biogen Idec have submitted a biologics license application to the FDA seeking approval to market Tysabri in the US as a treatment for Crohns disease. PanGenetics B.V. Licenses Therapeutic Antibody for Treatment of Pain from Lay Line Genomics S.p.A. (Business Wire via Yahoo! Finance) UTRECHT, The Netherlands & CAMBRIDGE, England & ROME, Italy----PanGenetics B.V. and Lay Line Genomics S.p.A. jointly announced today that the companies have entered into a collaboration in the field of therapeutic antibodies for the treatment of pain. Research & Markets: One of UCB´s biggest-selling Products, Keppra, Achieved Sales Growth of 34% (wallstreet:online AG) Research and Markets (http://www.researchandmarkets.com/reports/c47159) has announced the addition Calendar (Baltimore Sun) Events, screenings, support groups and more
Back to Crohns Disease News Archive
|
|